

**Genomic DNA from *Campylobacter jejuni*, Strain INP21**

**Catalog No. NR-3061**

**For research use only. Not for human use.**

**Contributor:**

Irving Nachamkin, Professor of Pathology and Laboratory Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA

**Manufacturer:**

BEI Resources

**Product Description:**

Genomic DNA was extracted from a preparation of *Campylobacter jejuni* (*C. jejuni*), strain INP21 (strain INP21 is also referred to as strain RM3148).<sup>1</sup> *C. jejuni*, strain INP21 was originally isolated by Irving Nachamkin and Patricia Arzarte in 1997 from a patient with Guillain-Barré syndrome at the National Institute of Pediatrics in Mexico City, Mexico.<sup>2,3</sup> In 2002, strain INP21 was deposited to the ATCC as Penner serotype HS:41.

NR-3061 has been qualified for PCR applications by amplification of approximately 1500 base pairs of the 16S ribosomal RNA gene.

**Material Provided:**

Each vial contains 0.7 µg to 1.5 µg of bacterial genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH ~ 8). Each vial of lot 7642596 contains 4 µg to 6 µg of bacterial genomic DNA in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH ~ 7.4). The concentration is shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

**Packaging/Storage:**

NR-3061 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from *Campylobacter jejuni*, Strain INP21, NR-3061."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed.

Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Parker, C. T., et al. "Comparison of *Campylobacter jejuni* Lipooligosaccharide Biosynthesis Loci from a Variety of Sources." J. Clin. Microbiol. 43 (2005): 2771-2781. PubMed: 15956396.
2. Engberg, J., et al. "Absence of Clonality of *Campylobacter jejuni* in Serotypes Other Than HS:19 Associated with Guillain-Barré Syndrome and Gastroenteritis." J. Infect. Dis. 184 (2001) 215-220. PubMed: 11400076.
3. Nachamkin, I., et al. "*Campylobacter jejuni* from Patients with Guillain-Barre Syndrome Preferentially Expresses a GD<sub>1a</sub>-Like Epitope." Infect. Immun. 70 (2002): 5299-5303. PubMed: 12183587.

ATCC® is a trademark of the American Type Culture Collection.



BEI Resources

[www.beiresources.org](http://www.beiresources.org)

E-mail: [contact@beiresources.org](mailto:contact@beiresources.org)

Tel: 800-359-7370

Fax: 703-365-2898